In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arbor Biotechnologies

https://arbor.bio/

Latest From Arbor Biotechnologies

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.

Deal Watch Business Strategies

Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate

Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Deal Watch: Coherus Terminates Immuno-Oncology Alliance With Junshi

Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.

Deal Watch Business Strategies

Gene Therapy: What To Expect Now And In The Future

The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.

FDA Gene Therapy
See All

Company Information

  • Industry
  • Digital Health
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Arbor
UsernamePublicRestriction

Register